ALK and non-small cell lung carcinoma: In NSCLC, new-generation targeted agents, such as osimertinib in the case of EGFR mutation other than exon 20 insertions [113,114], and alectinib, ceritinib, brigatinib, lorlatinib and ensartinib in the case of ALK translocation [115,116,117,118,119,120], have shown excellent results for patients with BMs, with intracranial overall response rates (ORRs) ranging between 78% and 91%, as well as encouraging tolerability results.